© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Mark Kieran, MD, PhD, director, Pediatric Medical Neuro-Oncology, Dana-Farber Cancer Institute, discusses the results of a study that evaluated dabrafenib as a treatment for pediatric patients with BRAF V600-mutant relapsed or refractory low-grade gliomas during an interview at the 2016 ESMO Congress.